<DOC>
	<DOCNO>NCT02611700</DOCNO>
	<brief_summary>This clinical study design phase 3 , multicenter , double-blind , randomize , control study , evaluate efficacy safety nimotuzumab combine paclitaxel+cisplatin（TP ) compare TP first-line treatment metastatic esophageal squamous carcinoma .</brief_summary>
	<brief_title>Nimotuzumab Combined With Paclitaxel Cisplatin Treatment Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>This clinical study design phase 3 , multicenter , double-blind , randomize , control study , evaluate efficacy safety nimotuzumab combine TP compare TP first-line treatment metastatic esophageal squamous carcinoma.The main endpoint OS .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Voluntary sign consent form ; 2 . Age≥18 year ; 3 . Histological diagnosis metastatic esophageal squamous cell carcinoma , include : ( 1 ) Naked metastatic esophageal cancer：have opportunity receive radical surgery radical radiation therapy ( 2 ) recurrent metastatic esophageal cancer：recurrence surgery adjuvant radiotherapy radical concurrent radio radiochemotherapy , n't receive systemic chemotherapy measurable lesion outside radiotherapy target zone ( 3 ) recurrent metastatic esophageal cancer , 6 month neoadjuvant adjuvant chemotherapy ; 4 . When patient need receive palliative radiotherapy , palliative radiotherapy complete 4 week target lesion outside radiotherapy target zone ( radiotherapy lesion include limited primary tumor , bone , lymph node ) ; 5 . According RECIST 1.1 criterion , least one measurable lesion exist ; 6 . Expected survival time 3 month ; 7 . Eastern Cooperative Oncology Group（ECOG）0 1 ; 8 . Normal bone marrow hematopoietic function ; total bilirubin acuities≤1.5×Upper Limit Of Normal（ULN） , creatinine≤1.0×ULN , aspartate aminotransferase（AST）/alanine aminotransferase（ALT）≤2.5×ULN , ALP≤5.0×ULN , creatinine clearance &gt; 60 ml/min , liver metastasis patient : AST/ALT≤5.0×ULN ; 9 . Take effective contraceptive measure growth period ; 10 . Compliance good . 1 . Have receive palliative chemotherapy metastatic esophageal cancer 2 . Recurrence metastasis neoadjuvant chemotherapy postoperative adjuvant &lt; 6 month ; 3 . Received kind radiotherapy within 4 week ; 4 . Patients receive palliative radiotherapy lesion one radiation zone ; 5 . Had receive adjuvant/neoadjuvant therapy use paclitaxel within 6 month ; 6 . Had receive adjuvant/neoadjuvant therapy cumulative dose cisplatin 300 mg/m2 ; 7 . Alone combined brain metastasis ; 8 . No measurable tumor lesion ; 9 . Combined primary malignant tumor ( except cure skin basal cell carcinoma cervical carcinoma situ ) ; 10 . Allergy component investigational drug ; 11 . Patients receive treatment chronic multiple dos corticosteroid ( inhaled steroid shortterm oral cortisol accord clinical indication allow ) ; 12 . Have n't recover degree 1 toxicity treatment . 13 . Concomitant severe cardiovascular disease , uncontrol heart failure , coronary heart disease , cardiomyopathy , arrhythmia , high blood pressure history myocardial infarction within 5 year ; 14 . Concomitant serious complication , activity digestive tract hemorrhage , perforation , severe jaundice , gastrointestinal obstruction , active clinical infection ( &gt; 2 level infection standard ) ; 15 . With chronic diarrhea disease renal insufficiency ; 16 . Have disease affect cognition mental abnormal ; 17 . Have severe acute chronic disease ; 18 . Pregnancy lactation woman ; 19 . Have participate clinical trial within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>